The EFPC provided its compliments with this highly ambitious agenda. From the Primary Care perspective many points are relevant and very much supported by the EFPC.

Very good is the wider scope of the EMA addressing problems with access and availability of drugs. We know it is difficult for political reasons to address the consequences of strategies of countries/pharmaceutical companies. Yet, it is an obligation to the EU-citizen to make absolute clear where the patient interest is not served by protective or marketing mechanisms. We miss that attention a little. We think the agenda could even more clearly focus on doing research where protective / self interest strategies of countries/ Pharma or other hindering mechanisms frustrate proper delivery/ research/ innovation.

EMA published its draft  ‘Regulatory Science to 2025’ strategy for a public consultation. This is a proposed plan for advancing the Agency’s engagement with regulatory science over the next five to ten years, covering both human and veterinary medicines. Stakeholders were invited to send comments and her you will be able to find the full EFPC response to the consultation.

Check here the full Survey with the EFPC Responses